BMS Reports Results from the P-III (KRYSTAL-12) Study of Krazati for the Treatment of Non-Small Cell Lung Cancer
Shots:
- BMS has revealed data from the P-III (KRYSTAL-12) clinical evaluation of Krazati vs SoC chemotherapy alone for the treatment of NSCLC associated with KRASG12C-mutation
- The study reached the 1EP demonstrating benefits in PFS and ORR with the drug vs SoC as a 2L treatment of NSCLC without any new safety outcomes. Trial is underway for further evaluation of endpoints incl. OS
- Additionally, the company’s sNDA for Krazati + cetuximab received priority review for previously treated KRASG12C-mutated locally advanced or metastatic CRC patients in Feb 2024 with the decision anticipated on Jun 21, 2024
Ref: BMS | Image: BMS
Related Posts:- BMS Reports the US FDA’s Acceptance of sNDA for the Combination of Krazati & Cetuximab with Priority Review to Treat Colorectal Cancer (CRC)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
